Seipel, K.; Brügger, Y.; Mandhair, H.; Bacher, U.; Pabst, T.
Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia. Int. J. Mol. Sci. 2022, 23, 12587.
https://doi.org/10.3390/ijms232012587
AMA Style
Seipel K, Brügger Y, Mandhair H, Bacher U, Pabst T.
Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences. 2022; 23(20):12587.
https://doi.org/10.3390/ijms232012587
Chicago/Turabian Style
Seipel, Katja, Yvo Brügger, Harpreet Mandhair, Ulrike Bacher, and Thomas Pabst.
2022. "Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia" International Journal of Molecular Sciences 23, no. 20: 12587.
https://doi.org/10.3390/ijms232012587
APA Style
Seipel, K., Brügger, Y., Mandhair, H., Bacher, U., & Pabst, T.
(2022). Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 23(20), 12587.
https://doi.org/10.3390/ijms232012587